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ABSTRACT Myosin-binding protein-C (MyBP-C) is a thick ﬁlament-associated protein that binds tightly to myosin. Given that
cMyBP-C may act to modulate cooperative activation of the thin ﬁlament by constraining the availability of myosin cross-bridges
for binding to actin, we investigated the role of MyBP-C in the regulation of cardiac muscle contraction. We assessed the Ca21
sensitivity of force (pCa50) and the activation dependence of the rate of force redevelopment (ktr) in skinned myocardium
isolated from wild-type (WT) and cMyBP-C null (cMyBP-C2/2) mice. Mechanical measurements were performed at 22C in the
absence and presence of a strong-binding, nonforce-generating analog of myosin subfragment-1 (NEM-S1). In the absence of
NEM-S1, maximal force and ktr and the pCa50 of isometric force did not differ between WT and cMyBP-C
2/2 myocardium;
however, ablation of cMyBP-C-accelerated ktr at each submaximal force. Treatment of WT and cMyBP-C
2/2 myocardium with
3 mM NEM-S1 elicited similar increases in pCa50, but the effects of NEM-S1 to increase ktr at submaximal forces and thereby
markedly reduce the activation dependence of ktr occurred to a greater degree in cMyBP-C
2/2 myocardium. Together, these
results support the idea that cMyBP-C normally acts to constrain the interaction between myosin and actin, which in turn limits
steady-state force development and the kinetics of cross-bridge interaction.
INTRODUCTION
Cardiac muscle contraction is initially triggered by the
binding of Ca21 to troponin C (TnC), which activates the
thin ﬁlament via a series of intermolecular events involving
TnI, TnT, and tropomyosin (1). Although Ca21 binding to
TnC is a vital component of the regulation of muscle con-
traction, it is well established that binding of Ca21 to TnC
alone is unable to fully activate the thin ﬁlament. Instead the
development of steady-state force and the kinetics of force
development result from the synergistic actions of Ca21
binding to TnC and strong binding of myosin cross-bridges to
actin (2–4). This synergy is evident in the biphasic form of the
force-pCa (pCa =2log[Ca2+]) relationship commonly seen in
skinned myocardial preparations, which is steeper at low
levels of Ca21 activation (i.e., forces ,0.50 Po) than at high.
If force development was solely regulated by the noncoop-
erative binding of Ca21 to TnC, the steepness (i.e., Hill
coefﬁcient, nH) of the force-pCa relationship should be ;1,
since cardiac TnC contains a single low afﬁnity Ca21-speciﬁc
binding site (5). However, the steepness of the force-pCa
relationship in cardiac muscle is relatively high (i.e., nH . 4)
(6–8), which strongly suggests the involvement of cooperative
interactions in the Ca21 activation process (4,9). Such
cooperative processes may include the synergistic effects of
strongly bound cross-bridges to enhance Ca21 binding to TnC
and to directly recruit additional cross-bridges to strong binding
states, i.e., cross-bridge-induced cross-bridge binding (9).
With regard to cooperative activation of myocardium,
most research to date has focused primarily on the roles
played by thin ﬁlament regulatory proteins such as TnT
(1,4), and comparatively little work has been done to deter-
mine the degree to which thick ﬁlament accessory proteins
modulate cooperative activation of the thin ﬁlament. One
prospective thick ﬁlament protein is myosin-binding protein-
C (MyBP-C), which in skeletal muscle is localized in dis-
crete bands (;7–9) spaced at regular intervals (;43 nm)
along the central region of each half of the A-band (10,11).
MyBP-C is thought to restrict cross-bridge binding to actin,
possibly by tethering the myosin cross-bridge to the thick
ﬁlament backbone (12–14) via interactions of two myosin-
binding domains within MyBP-C to light meromyosin and
subfragment 2 (15,16). These binding domains may act in
concert (17) or independently (18,19) to tether the myosin
heads to the thick ﬁlament. MyBP-C was originally proposed
to form a trimeric collar around the thick ﬁlament (20),
thereby providing a reasonable explanation for cross-bridge
tethering, and recent work by Watkins and co-workers
(14,21) has provided experimental support for this idea.
To investigate the role of MyBP-C in the regulation of
myocardial contraction, in particular its effects on force and
the kinetics of force development, we previously developed
a cMyBP-C null mouse (cMyBP-C2/2) (22). Compared to
age-matched wild-type (WT) controls, cMyBP-C ablation
slightly reduced the Ca21 sensitivity of force but did not
affect maximum isometric force (19,22) and increased peak
normalized power output (23). Ablation also had striking
effects on in vivo left ventricular function, as manifested by
reduced peak systolic elastance, a marked abbreviation of the
time course of systolic ejection (24) and a prolonged duration
of isovolumic relaxation (22). Thus, in normal myocardium
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cMyBP-C appears to contribute signiﬁcantly to both systolic
and diastolic function.
Since cMyBP-C is postulated to constrain the availability
of myosin cross-bridges for binding to actin, we hypothe-
sized that cMyBP-C normally acts to limit cooperative acti-
vation of the thin ﬁlament. In this model, cMyBP-C functions
to attenuate steady-state force and repress the rate of force
development during submaximal activations. Thus, ablation
of cMyBP-C should increase steady-state isometric force and
accelerate the rate of force redevelopment during submax-
imal activation due to greater cross-bridge availability to
actin. Further, based on the premise that there is greater co-
operative activation of the thin ﬁlament by endogenous cross-
bridges in cMyBP-C2/2 myocardium, we hypothesized that
cMyBP-C2/2 myocardium would exhibit altered respon-
siveness to NEM-S1, a strong-binding nonforce-generating
derivative of myosin subfragment 1 (S1) that accelerates
force development at submaximal Ca21 concentrations inWT
myocardium. These ideas are investigated here by charac-
terizing the activation dependence of the rate of force devel-
opment (ktr) in skinned preparations isolated from both WT
and cMyBP-C2/2 myocardium.
MATERIALS AND METHODS
Experimental solutions
All activating solutions were prepared using the computer program of
Fabiato (25) with stability constants corrected to pH 7.0 and 22C listed by
Godt and Lindley (26). The composition of relaxing solution was as follows
(in mM): 100 KCl, 20 imidazole, 4 MgATP, 2 EGTA, and 1 Mg21free; pH 7.0
at 22C. All activating solutions contained (in mM): 100 N,N-bis[2-
hydroxyethyl]-2-aminoethanesulfonic acid (BES), 15 creatine phosphate,
and 5 1,4-dithiothreitol (DTT). Furthermore, pCa 9.0 solution contained (in
mM): 7 EGTA, 5.49 MgCl2, 4.66 ATP, and 0.017 CaCl2; pCa 4.5 solution
contained (in mM): 7 EGTA, 5.29 MgCl2, 4.72 ATP, and 7.01 CaCl2; and
preactivating solution contained (in mM): 5.29 MgCl2, 4.67 ATP, and 0.07
EGTA. All activating solutions had an ionic strength of 180mM (adjustedwith
potassium propionate) and a pH of 7.0 at 22C. A range of pCa solutions
containing differing concentrations of free Ca21 (i.e., pCa 6.2–5.4) were
prepared by mixing appropriate volumes of pCa 9.0 and pCa 4.5 solutions.
Experimental animals
Homozygous cardiac MyBP-C knockout mice (cMyBP-C2/2) were gener-
ated as described previously (22) and were maintained on an SV/129 back-
ground. Age-matched (i.e., 3–6 months) WT SV/129 mice were obtained
from Taconic Farms (Germantown, NY). All animal usage was conducted
under the strict guidelines established by the University ofWisconsin Animal
Care and Use Committee.
Preparation of skinned myocardium
Chemically skinned myocardial preparations were obtained from cMyBP-
C2/2 and WT hearts as described previously (27). Brieﬂy, both cMyBP-C2/2
and WT mice were injected intraperitoneally with heparin (5,000 U heparin/
kg body wt). After 20 min, the mice were placed in a glass bell jar and
were anesthetized with inhaled isoﬂurane. After the establishment of
deep anesthesia, conﬁrmed by the loss of the pedal reﬂex and lack of
muscular tension in the limbs, the mice were euthanized by inducing a
pneumothorax. The heart was rapidly excised and the left and right
ventricles were isolated in Ca21-free Ringer’s solution containing (in mM):
118 NaCl, 4.8 KCl, 2 NaH2PO4, 1.2 MgCl2, 25 HEPES, 11 glucose, and
0.5 CaCl2, pH 7.4 at 22C. The ventricles were immediately frozen in liquid
N2 for 10 min to improve the subsequent quality of mechanical preparations.
The frozen ventricles were thawed and homogenized with a Polytron
(Lucern, Switzerland) homogenizer for ;2 s in ice-cold relaxing solution.
The cellular homogenate was centrifuged at 120 3 g for 1 min and resus-
pended in fresh ice-cold relaxing solution. After a second centrifugation, the
pelleted myocardial preparations were resuspended in fresh relaxing solution
containing 250 mg/ml saponin and 1% Triton X-100 for 30 min at 22C. The
chemically skinned preparations were washed three times with ice-cold
relaxing solution and allowed to settle. After the ﬁnal wash, the skinned
myocardial preparations were dispersed in a glass petri dish with 50 ml of
ice-cold fresh relaxing solution. The petri dish was kept on ice at all times
until use. Mechanical experiments were always performed on cardiac
preparations isolated on the day of the experiments. Despite exhibiting
signiﬁcant cardiac hypertrophy (22), skinned cardiac preparations from
cMyBP-C2/2 hearts did not show observable differences in ultrastructure or
striation pattern compared with WT cardiac preparations.
Experimental apparatus
Skinned preparations with well-deﬁned edges and no free ends evident in the
middle region were transferred from the petri dish to a stainless steel ex-
perimental chamber (28) containing fresh relaxing solution. For mechanical
measurements, skinned myocardial preparations (dimensions: ;800 mm 3
100–200 mm) were mounted between a force transducer (model 403A;
Aurora Scientiﬁc; Aurora, Ontario, Canada) and a motor (model 312B,
Aurora Scientiﬁc). A 500-mm long myocardial segment remained exposed
to the solution between the force transducer and motor. Before mechanical
measurements, the experimental apparatus was set on the stage of an in-
verted microscope (Olympus; Tokyo, Japan) ﬁtted with a 403 objective and
a closed-circuit television camera (model WV-BL600; Panasonic; Tokyo,
Japan). Light from a halogen lamp was passed through a cut-off ﬁlter
(transmission .620 nm) and was used to illuminate the skinned myocar-
dium. Sarcomere length and myocardial dimensions were recorded during
relaxation and activation using the video camera and a VHS recorder (model
SVO-1420; Sony; Tokyo, Japan). Activated cardiac preparations that
exhibited length changes .5% of initial sarcomere length were discarded
and the data not used. Changes in force and motor position were sampled
(16-bit resolution, DAP5216a; Microstar Laboratories; Bellevue, WA) at
2.0 kHz with SLControl software (29) and saved to computer ﬁles for later
analysis. Changes in force were also recorded on a chart recorder using a
slow time base. All experiments were performed at 22C and at a sarcomere
length of ;2.20 mm measured in relaxing solution.
Preparation and use of NEM-S1
Myosin S1 was puriﬁed from rabbit fast-twitch skeletal muscle and modiﬁed
with N-ethylmaleimide (NEM), as described previously (30). Although
NEM-S1 signiﬁcantly increases myosin ATPase activity in solutions con-
taining myosin, regulated actin, and Ca21 (31,32), it exhibits no ATPase ac-
tivity of its own (31). NEM-S1 forms long-lasting complexes with actin in
the presence or absence of Ca21 and ATP (30). In this study, the con-
centration of NEM-S1 was estimated by absorbance at 280 nm (with light-
scattering correction performed at 320 nm) using a mass absorptivity of 0.75
and a molecular mass of 118 kDa for myosin S1. A stock solution of NEM-
S1 (i.e., 20–30 mM) was prepared by overnight dialysis against a solution of
20 mM imidazole, pH 7.0, and 1 mM DTT. A working solution of NEM-S1
(i.e., 10–15 mM) was prepared immediately before use by mixing equal
volumes of 23 stock of pCa 9.0 solution and NEM-S1 stock. The
concentration of NEM-S1 was adjusted by adding the appropriate amount of
13 pCa 9.0 solution. Before any mechanical measurements, each skinned
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myocardial preparation was incubated for 15 min at 22C in solution of pCa
9.0 containing either 1 or 3 mM NEM-S1. Thereafter, for measurements of
force or the rate of force development, the preparation was initially incu-
bated with NEM-S1 in a solution of pCa 9.0 to allow for NEM-S1-binding to
actin and was subsequently transferred to preactivating solution for 1 min
and then into activating solutions of varying pCa (i.e., pCa 6.2–4.5) without
NEM-S1 (30). After each mechanical measurement, the preparation was
returned to solution of pCa 9.0 containing NEM-S1. Thus, the preparation
was incubated in NEM-S1-free activating solutions for no more than 2 min,
during which time negligible amounts of NEM-S1 would be debound (30).
Speciﬁc experimental protocols
Rate of tension development
The rate constant of force redevelopment (ktr) in skinned myocardium was
assessed using a modiﬁcation of the experimental protocol originally de-
scribed by Brenner and Eisenberg (33). Measurement of ktr involves a
mechanical slack-restretch maneuver to detach bound myosin cross-bridges
from actin in steadily Ca21-activated myocardium. Each skinned prepara-
tion was transferred from relaxing to activating solutions of varying free
Ca21 (i.e., pCa 6.2–4.5) and allowed to generate steady-state force. The
myocardial preparation was rapidly (,2 ms) slackened by 20% of its orig-
inal length, resulting in a rapid reduction of force to near zero (i.e., ,5% of
steady isometric force). This was followed by a brief period of unloaded
shortening (i.e., 20 ms) after which the preparation was rapidly restretched to
its original length. Force redevelopment after the slack-restretch maneuver
and force recovery to the original steady-state value reﬂects the rate of
myosin cross-bridge cycling between weakly bound and strongly bound,
force-generating states (33). A ktr-pCa relationship was obtained by initially
activating the skinned myocardium in solution of pCa 4.5 and then in a series
of submaximally activating solutions between pCa 6.2 and 5.4. To assess
any decline in the maximal rate of force redevelopment, the preparation was
activated in a solution of pCa 4.5 at the end of each experimental protocol.
The decline in maximum force at pCa 4.5 during the experiment was usually
,10%, but preparations showing decreases .15% were discarded and the
data not used. The reference value of maximal ktr for each activation was
obtained by interpolation between the initial and ﬁnal measurements of
maximal ktr. The apparent rate constants of force redevelopment (ktr) were
estimated by linear transformation of the half-time of force redevelopment,
i.e., ktr ¼ 0.693/t1/2, as described previously (34,35).
Force-pCa relationship
During measurements of force redevelopment, each preparation was to
develop steady force in solutions of varying free Ca21. The difference be-
tween steady-state force and the force baseline obtained after the 20% slack
step was measured as the total force at that free [Ca21]. Active force was
then calculated by subtracting Ca21-independent force in solution of pCa
9.0 from the total force and was normalized to the cross sectional area of
the preparation, which was calculated from the width of the preparations
assuming a cylindrical cross section. Force-pCa relationships were derived
by expressing submaximal force (P) at each pCa as a fraction of maximal
force (Po) determined at pCa 4.5, that is, P/Po. The apparent cooperativity in
the activation of force development was inferred from the steepness of the
force-pCa relationship and was quantiﬁed using a Hill plot transformation
of the force-pCa data (36). The force-pCa data were ﬁt using the equation
P/Po ¼ [Ca21]n/(kn 1 [Ca21]n), where n is the Hill coefﬁcient and k is the
[Ca21] required for half-maximal activation (i.e., pCa50).
Statistics
All data are expressed as mean6 SE. Where appropriate, either a two-tailed
t-test for independent samples or a paired t-test was used as a post hoc test of
signiﬁcance, with signiﬁcance set at p , 0.05.
RESULTS
Steady-state mechanical properties in WT
and cMyBP-C2/2 skinned myocardium
Ablation of cMyBP-C had no signiﬁcant effects on either
Ca21-independent force, measured in pCa 9.0, or maximal
Ca21-activated force (Table 1). Furthermore, we observed
no signiﬁcant difference in the Ca21 sensitivity of force, that
is, mean pCa50 was 5.73 6 0.01 in WT myocardium and
5.72 6 0.01 in cMyBP-C2/2 myocardium. Although mean
pCa50 was similar between groups, we observed a small, but
signiﬁcant increase in Ca21-activated forces at low Ca21
concentrations, i.e., pCa$ 5.9 in cMyBP-C2/2myocardium
(Fig. 1 A). These results are consistent with the idea that
elimination of cMyBP-C promotes increased binding of
cross-bridges to actin. Consistent with the increase in Ca21-
activated force at low [Ca21], we observed a signiﬁcant
reduction in the steepness of the force-pCa relationship
for Ca21-activated forces ,0.50 Po in cMyBP-C
2/2 myo-
cardium (n2 was 4.06 0.2 vs. 5.66 0.1 in WT myocardium;
p , 0.05). These data indicate that ablation of cMyBP-C
reduces the apparent cooperativity of force development.
TABLE 1 Steady-state mechanical measurements in skinned preparations from WT and cMyBP-C2/2 myocardium
Group Po (mN mm
2) Prest (mN mm
2) n2 n1 pCa50
WT myocardium
Control (12) 20.7 6 2.3 0.8 6 0.1 5.6 6 0.1 2.7 6 0.1 5.73 6 0.01
1 mM NEM-S1 (9) 18.2 6 1.7 1.6 6 0.8* 3.3 6 0.1* 2.6 6 0.2 5.72 6 0.01
3 mM NEM-S1 (12) 15.2 6 1.5 2.3 6 0.4* 2.6 6 0.2* 2.2 6 0.2 5.79 6 0.01*
cMyBP-C/ myocardium
Control (10) 18.4 6 2.3 0.8 6 0.1 4.0 6 0.2*y 2.5 6 0.5 5.72 6 0.01
1 mM NEM-S1 (9) 17.0 6 1.9 1.9 6 0.3* 2.8 6 0.2*y 2.1 6 0.1 5.72 6 0.01
3 mM NEM-S1 (7) 15.7 6 1.6 3.7 6 0.4*y 1.5 6 0.4*y 2.1 6 0.5 5.82 6 0.02*
All values are expressed as mean 6 SE, with the number of experimental preparations given in parentheses.
Po, maximal Ca
21-activated force at pCa 4.5; Prest, Ca
21-independent force at pCa 9.0; n2, Hill coefﬁcient for Ca
21-activated force ,0.50 Po; n1,
Hill coefﬁcient for Ca21-activated force .0.50 Po; pCa50, pCa required for half-maximal activation.
*Signiﬁcantly different from control (p , 0.05).
ySigniﬁcantly different from WT (p , 0.05).
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The effect of NEM-S1 on steady-state force
Our previous studies of cooperative mechanisms in skinned
skeletal muscle ﬁbers (30,35) and skinned myocardium (37)
have used NEM-S1, a strong-binding, nonforce-generating
derivative of myosin subfragment-1 (S1), to mimic the acti-
vating effects of endogenous strong-binding myosin cross-
bridges. Those studies showed that 6–10 mM NEM-S1 is an
upper limit in such experiments, since higher levels resulted
in a marked decrease in maximal Ca21-activated force (Po),
presumably due to competitive inhibition of endogenous
cross-bridge binding (30). In addition to its effects on steady-
state force, treatment with 6 mM NEM-S1 nearly eliminated
the activation dependence of the rate of force redevelopment
and dramatically slowed the rate of force relaxation in WT
skinned myocardium (37). Thus, to avoid saturating the
cooperative mechanisms underlying activation of force in
cardiac muscle, we used suboptimal concentrations of NEM-
S1 (i.e., 1 mM or 3 mM) to examine the responsiveness of
cMyBP-C2/2myocardium to the activating effects of strong-
binding cross-bridges.
The effects of 1 and 3 mM NEM-S1 on Ca21-independent
force, maximal Ca21-activated force, the Ca21 sensitivity of
force, and the steepness (i.e., n2 and n1) of the force-pCa
relationship are summarized in Table 1. In both WT and
cMyBP-C2/2 myocardium, NEM-S1 increased both Ca21-
independent and submaximal Ca21-activated forces (Table
1) in a concentration-dependent manner, i.e., the Ca21-
sensitivity of force (pCa50) increased signiﬁcantly in both
WT and cMyBP-C2/2 myocardium. Furthermore, NEM-S1
signiﬁcantly reduced the steepness (n2) of the force-pCa
relationship for Ca21-activated forces ,0.50 Po in a con-
centration-dependent manner, an effect that was greater in
cMyBP-C2/2 myocardium (Fig. 1 B).
Acceleration of cross-bridge kinetics by NEM-S1
The rate constant of force redevelopment (ktr) after rapid release
and restretch (33) provides an estimate of the rate of transition
from weak-binding, nonforce-generating cross-bridges to
strong-binding, force-generating cross-bridges in skeletal and
cardiac muscles. Cooperative interactions within or along the
thin ﬁlament, such as cross-bridge-induced cross-bridge bind-
ing, havebeenproposed to slow the rateof force redevelopment
(38), thereby providing the basis for the steep activation
dependence of ktr in cardiac muscle observed previously
(27,37,39–41). If cMyBP-Cconstrains the availability of cross-
bridges to actin, then removal of cMyBP-C should increase the
rate of force redevelopment due, at least in part, to enhanced
cross-bridge-induced binding of endogenous cross-bridges.
Initial experiments were conducted in the absence of NEM-S1
to establish whether ablation of cMyBP-C accelerated the
kinetics of cross-bridge interaction at all levels of submaximal
activation. Experimentswere then conducted in the presence of
NEM-S1 to determine the effects of strong-binding cross-
bridges on the activation dependence of the rate of force re-
development in WT and cMyBP-C2/2 myocardium.
Records of the time course of force redevelopment ob-
tained in the absence and presence of NEM-S1 are shown in
Fig. 2 for both WT and cMyBP-C2/2myocardium. Ablation
of cMyBP-C accelerated the rate of force redevelopment as
compared to WT at each submaximal [Ca21] in both the
absence (Fig. 2 A) and presence (Fig. 2 B) of NEM-S1. We
observed a steep activation dependence of the rate of force
redevelopment as the level of Ca21 activation was varied
FIGURE 1 Effect of NEM-S1 on force-pCa relationships in skinned
myocardium from WT and cMyBP-C2/2. (A) All values are mean 6 SE.
Smooth lines were generated by ﬁtting the mean data to a Hill equation:
P/Po ¼ [Ca21]n/(kn 1 [Ca21]n), where n is the Hill coefﬁcient and k is the
[Ca21] required for half-maximal activation (pCa50). The relationships
between Ca21-activated force and pCa were determined in the absence
(open symbols) and presence (solid symbols) of 3 mM NEM-S1. pCa50
values for WT were control (s), 5.73 6 0.01; 3 mM NEM-S1 (d), 5.79 6
0.01, whereas pCa50 values for cMyBP-C
2/2 were control (D), 5.726 0.01;
3 mMNEM-S1 (:), 5.826 0.01. (B) Hill plot transformations of the force-
pCa data were generated using the following equation: log[Prel/(12 Prel)]¼
n(log[Ca21] 1 k), where Prel is force as a fraction of Po, n is the Hill
coefﬁcient, and k is the [Ca21] required for half-maximal activation (pCa50).
All values are mean 6 SE. Fiber characteristics are listed in Table 1.
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from near threshold to maximal levels in both WT and
cMyBP-C2/2 myocardium. A summary of the ktr and
relative ktr values for several levels of Ca
21 activation is
presented in Table 2. The cumulative ktr-pCa relationships
obtained in the absence and presence of 3 mM NEM-S1 are
presented in Fig. 3. In the absence of NEM-S1, ktr varied
with level of activation in both WT (1.4 6 0.2 s21 at pCa
6.0–30.06 1.5 s21 at pCa 4.5) and cMyBP-C2/2 (4.26 0.2
s21 at pCa 6.1–30.6 6 0.8 s21 at pCa 4.5) myocardium.
However, addition of 3 mM NEM-S1 signiﬁcantly reduced
the Ca21 dependence of ktr in both WT (22.8 6 0.8 s
21 at
pCa 6.2–29.1 6 1.0 s21 at pCa 4.5) and cMyBP-C2/2 (30.0
6 1.1 s21 at pCa 6.2–29.5 6 0.8 s21 at pCa 4.5) myo-
cardium.
The rate constant of force redevelopment was also plotted
versus steady-state isometric force at each pCa to assess the
variation of ktr as a function of the level of thin ﬁlament
activation, induced by both Ca21 and strong-binding cross-
bridge (Fig. 4). In the absence of NEM-S1, ktr increased as a
function of steady-state isometric force in WT myocardium,
gradually at low forces and more steeply at high forces.
However, in cMyBP-C2/2 myocardium, we observed sig-
niﬁcantly faster rates of force redevelopment at all levels of
submaximal activation compared to that observed in WT
myocardium. These data are consistent with the idea that in
normal myocardium, cMyBP-C constrains and thereby re-
duces the cooperative binding of endogenous cross-bridges
to actin and in this way contributes to the activation depen-
dence of the rate of force redevelopment. As seen in previous
studies (37,39), the ktr-isometric force relationship was dra-
matically altered after NEM-S1 treatment. In WT myocardium,
treatment with 3 mM NEM-S1 increased the rate of force
redevelopment at low levels of activation to values near those
obtained in maximally activated preparations. At intermedi-
ate levels of activation, NEM-S1 increased ktr in WT myocar-
dium to values greater than those measured in control at
similar relative isometric forces, but still less than the values
obtained at both low and maximum Ca21-activated forces.
Treatment with NEM-S1 had qualitatively similar effects on
the ktr-isometric force relationship in cMyBP-C
2/2 myocar-
dium. But at all levels of submaximal activation, ktr values
measured in cMyBP-C2/2 myocardium were signiﬁcantly
faster than those measured in WT myocardium.
DISCUSSION
cMyBP-C is thought by many investigators to tether myosin
cross-bridges to the thick ﬁlament, which would effectively
control the availability of cross-bridges for binding to actin
(12–14). Based on this premise, we investigated the idea that
this constraint on cross-bridge availability would reduce the
cooperative activation of force and the rate of force devel-
opment by strong-binding cross-bridges during submaximal
activations with Ca21. We measured the activation depen-
dence of isometric force and the rate constant of force de-
velopment (ktr) in skinned myocardium from WT and
cMyBP-C2/2 mice. Experiments were done both in the
absence and in the presence of NEM-S1 to determine the
extent to which cMyBP-C modulates the responsiveness of
the myocardial thin ﬁlament to the activating effects of
strong-binding cross-bridges. In the absence of NEM-S1,
WT and cMyBP-C2/2 myocardium differed with regard to
force generation. cMyBP-C2/2 myocardium exhibited 1), a
small, but signiﬁcant increase in steady-state force at low
levels of Ca21 activation (Fig. 1 A), 2), a concomitant re-
duction in the steepness of the force-pCa relationship (Fig.
1 B), and 3), markedly greater rates of force development
(ktr) during submaximal levels of Ca
21 activation (Figs. 3
and 4). Treatment of WT and cMyBP-C2/2myocardium with
3 mM NEM-S1 1) elicited signiﬁcant increases in submax-
imal Ca21-activated force (Fig. 1 A), with a corresponding
increase in the Ca21 sensitivity of force; and 2) markedly
accelerated the rate of force development during submaximal
levels of Ca21 activation (Figs. 3 and 4), consistent with
earlier results from WT myocardium (39). However, the
activating effects of strong-binding cross-bridges were more
pronounced in cMyBP-C2/2 myocardium, suggesting that
ablation of cMyBP-C further promotes cooperative interac-
tions within the thin ﬁlament.
TABLE 2 Summaries of ktr and Ca
21-activated force after treatment with NEM-S1
WT cMyBP-C/
Control 1 mM NEM-S1 3 mM NEM-S1 Control 1 mM NEM-S1 3 mM NEM-S1
pCa 4.5
ktr (s
1) 30.0 6 1.5 29.6 6 0.6 29.1 6 1.0 30.6 6 0.8 29.6 6 0.7 29.5 6 0.8
pCa 6.0
Force (P/Po) 0.04 6 0.01 0.12 6 0.01 0.23 6 0.02 0.07 6 0.01 0.13 6 0.02 0.29 6 0.03
ktr (s
1) 1.4 6 0.2 12.2 6 1.1 18.2 6 0.7 3.6 6 0.2 15.6 6 0.5 24.3 6 1.1
Relative ktr 0.05 6 0.01 0.41 6 0.04 0.63 6 0.03 0.12 6 0.01 0.56 6 0.04 0.83 6 0.06
pCa 5.8
Force (P/Po) 0.40 6 0.02 0.38 6 0.03 0.52 6 0.02 0.38 6 0.01 0.38 6 0.02 0.53 6 0.03
ktr (s
1) 3.3 6 0.4 5.8 6 0.3 11.1 6 0.5 8.5 6 0.3 10.4 6 0.4 21.3 6 0.9
Relative ktr 0.11 6 0.01 0.20 6 0.01 0.38 6 0.01 0.28 6 0.01 0.37 6 0.03 0.73 6 0.05
All values are expressed as mean 6 SE. P/Po, relative Ca
21-activated tension; ktr, rate of tension redevelopment in s
21; and relative ktr, the relative rate
of tension redevelopment. Both P/Po and relative ktr values obtained in pCa 6.0 and pCa 5.8 were normalized to maximal values obtained in pCa 4.5.
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Steady-state mechanical properties
of cMyBP-C2/2 myocardium
Steady-state isometric force
Ablation of cMyBP-C did not affect either the Ca21 sen-
sitivity of force or maximal Ca21-activated force (Table 1);
however, there was a small but signiﬁcant increase in steady-
state force at low levels of Ca21 activation compared to WT
(Fig. 1 A), with a corresponding reduction in steepness of the
force-pCa relationship for forces ,0.50 Po (Fig. 1 B). The
increase in submaximal force is consistent with the idea that
cMyBP-C normally depresses the availability of myosin to
actin, presumably via binding of the N-terminus of cMyBP-C
to the S2 domain of myosin (42), i.e., ablation of cMyBP-C
would eliminate this interaction and lead to greater proba-
bility of myosin binding to actin. The ﬁnding that there was
no difference between cMyBP-C2/2 and WT myocardium
FIGURE 3 Effect of NEM-S1 on the Ca21 dependence of the rate of force
redevelopment. Force redevelopment after rapid release and restretch was
measured as a function of pCa in skinned myocardium from WT (s,d) and
cMyBP-C2/2 (D,:) in the absence (open symbols) and presence (solid
symbols) of 3 mMNEM-S1. All values are mean6 SE. Fiber characteristics
are listed in Table 2.
FIGURE 2 Rate of force redevelopment in skinned myocardium fromWT
and cMyBP-C2/2. Differences in the rate constant of force redevelopment (ktr)
were expressed relative to respective peak forces. (A) The rates of force
redevelopment measured in the absence of NEM-S1 from two representative
skinned myocardial preparations from either WT (left trace: pCa 4.5, P/Po ¼
1.0, ktr¼ 34.7 s21; right trace: pCa 5.8, P/Po¼ 0.40, ktr¼ 5.1 s21) or cMyBP-
C2/2 (middle trace: pCa 5.8, P/Po¼ 0.40, ktr¼ 11.4 s21). (B) The rates of force
redevelopment measured in the presence of NEM-S1 from two representative
skinned myocardial preparations from either WT (left trace: pCa 4.5, P/Po ¼
1.0, ktr¼ 33.0 s21; right trace: pCa 5.8, P/Po¼ 0.55, ktr¼ 16.1 s21) or cMyBP-
C2/2 (middle trace: pCa 5.8, P/Po ¼ 0.57, ktr ¼ 23.5 s21).
FIGURE 4 Effect of NEM-S1 on the activation dependence of the rate of
force redevelopment. Force redevelopment after rapid release and restretch
was measured as a function of relative steady-state isometric force (P/Po)
in skinned myocardium from WT (s,d) and cMyBP-C2/2 (D,:) in
the absence (open symbols) and presence (solid symbols) of 3 mMNEM-S1.
All values are mean 6 SE. Fiber characteristics are listed in Table 2.
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with respect to force at activation levels above half-maximal
suggests that the activating effects of the small increase in
bound cross-bridges with cMyBP-C ablation were obscured
by the much greater activating effects of Ca21 binding at
higher levels of activation. Interestingly, in earlier studies,
the acute extraction of cMyBP-C from rat myocardium
resulted in increases in the Ca21 sensitivity of force (12,13)
and maximum force (13), which were not observed here
(other than the increases in force at very low [Ca21]). The
differences in effects due to acute versus chronic ablation
suggest that over time there are compensatory changes within
the thick or thin ﬁlaments of cMyBP-C2/2 myocardium that
diminish or repress the effects on force due to cMyBP-C
ablation. Although we haven’t yet identiﬁed these compen-
satory changes, we have eliminated several possibilities such
as myosin heavy chain expression (22) and troponin I phos-
phorylation (23), which are virtually unchanged in cMyBP-
C2/2 myocardium.
Rate of force development
Several investigators have reported that the rate of force
development (ktr) in cardiac muscle is highly activation
dependent (37,40,43,44), increasing ;10-fold from low to
high levels of activation. Typically, ktr is thought to be the
sum of the forward (fapp) and reverse (gapp) rate constants
describing the transition between force-generating and
nonforce-generating states (33). A recent model by Camp-
bell (38,45) predicts that activation dependence of ktr is a
consequence of cooperativity in cross-bridge binding to the
thin ﬁlament. At low levels of Ca21, the number of
noncycling cross-bridges is high, so that progressive re-
cruitment of cross-bridges from this pool would act to slow
the overall rate of force development. The ﬁrst cross-bridges
that bind recruit additional cross-bridges, which subse-
quently bind and recruit more cross-bridges and so forth,
until force reaches a steady-state level. Thus, the rate of force
development is slow at low Ca21 due to progressive co-
operative recruitment of cross-bridges to force-generating
states. At higher levels of Ca21, the cooperative slowing of
force development is reduced because Ca21-binding to TnC
would immediately recruit most cross-bridges into the cycl-
ing pool, leaving relatively few noncycling cross-bridges avail-
able for cooperative recruitment.
In this study, ablation of cMyBP-C accelerated ktr mea-
sured during submaximal activations. MyBP-C is associated
with the thick ﬁlaments, and based on studies of skeletal
muscle (10) its location is presumably limited to a series of
transverse stripes within the C-zones of the A-bands, such
that the stoichiometric relationship between cMyBP-C and
myosin cross-bridges is;1 cMyBP-Cmolecule for every 7–9
cross-bridges (10). This stoichiometry implies that cMyBP-C
exerts its effects directly on only a small subset of cross-
bridges, so that any effects of cMyBP-C on cross-bridge
function are limited to a relatively small fraction of the total
or are somehow communicated to other cross-bridges or to
thin ﬁlament functional groups to alter contractile properties
of the myoﬁlament. Our results don’t eliminate any of these
possibilities but strongly support the idea that cMyBP-C
modulation of cross-bridge availability inﬂuences the level
of thin ﬁlament activation. Consistent with this idea, ablation
of cMyBP-C resulted in a signiﬁcant acceleration of the
kinetics of force development at all levels of submaximal
Ca21 activation, but themost pronounced effects on the kinet-
ics of force development occurred at low levels of activation
where cooperative activation is most pronounced (9). The
dramatic acceleration of cross-bridge kinetics observed in
cMyBP-C2/2myocardium at low levels of activation is to be
disproportionate with the modest increases in submaximal
Ca21-activated force in cMyBP-C2/2 myocardium, which
provides further support to the idea that the kinetics of force
development in myocardium are sensitive to even small
increases in numbers of cross-bridges (9).
Hofmann et al. (12) proposed that cMyBP-C tethers cross-
bridges to the thick ﬁlament backbone and thereby represses
their interaction with actin. Recent work has identiﬁed dis-
tinct structural domains within cMyBP-C that could con-
tribute to formation of a collar around the thick ﬁlament,
whereas other domains in N-terminal regions of cMyBP-C
interact with the S2 domain of myosin (21). Eliminating
cMyBP-C would also eliminate these interactions and pre-
sumably increase the mobility of cross-bridges and the likeli-
hood of their interaction with actin, particularly at low levels
of Ca21. In cMyBP-C2/2myocardium, there is greater prob-
ability that the thin ﬁlament will be cooperatively activated
by strong-binding cross-bridges at low levels of Ca21 acti-
vation, which would reduce the slope of the force-pCa
relationship and accelerate the rate of force development and
in turn reduce the apparent cooperativity of the activation
process. Consistent with this idea, the rate of force redevel-
opment was accelerated during submaximal Ca21 activations
of cMyBP-C2/2 myocardium (Fig. 4). As observed previ-
ously (23), we did not observe any signiﬁcant differences in
the maximal rate of force redevelopment of cMyBP-C2/2
and WT myocardium. This result is predictable given that at
saturating levels of Ca21 (pCa 4.5), there is little, if any, co-
operative recruitment of cross-bridges.
Effects of strong-binding myosin cross-bridges
Force development in cardiac muscle appears to be very
sensitive to the effects of even small numbers of strong-
binding cross-bridges to cooperatively activate the myocar-
dial thin ﬁlament (4,37,40,41). This feature of cardiac muscle
suggested to us that ablation of cMyBP-C and the concom-
itant increase in endogenous strong-binding cross-bridges at
submaximal concentrations of Ca21 would alter the respon-
siveness of the cardiac thin ﬁlament to the activating effects of
NEM-S1. In WT myocardium, the activating effects of
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strong-binding cross-bridges is particularly evident even at
very low levels of Ca21 (e.g., pCa 9.0), where virtually no
Ca21 is bound to TnC. Previous studies (37) showed that
treatment of rat skinned myocardium with 6 mM NEM-S1
elicited a Ca21-independent force that was;20%ofmaximal
Ca21-activated force. In this study, 3 mM NEM-S1 evoked
Ca21-independent forces that were 15% of maximal in WT
myocardium and 24% of maximal in cMyBP-C2/2 myocar-
dium. Furthermore, whereas the Ca21 sensitivity of force did
not differ between WT and cMyBP-C2/2 myocardium, we
observe a greater NEM-S1-induced increase in submaximal
force in cMyBP-C2/2 myocardium compared to WT. The
greater responsiveness of cMyBP-C2/2myocardium to 3mM
NEM-S1 supports the idea that ablation of cMyBP-C pre-
disposes the thin ﬁlament to increased activation by strong-
binding cross-bridges.
NEM-S1 treatment of WT and cMyBP-C2/2myocardium
also accelerated the rate of force redevelopment at low Ca21;
however, as was seen in the effects of NEM-S1 on steady
force, the rate of force redevelopment was increased to a
much greater degree in cMyBP-C2/2 myocardium. In fact,
NEM-S1-treated cMyBP-C2/2 myocardium exhibited rates
of force redevelopment at low [Ca21] (Fig. 4), similar to
those observed during maximal activation. Thus, NEM-S1
signiﬁcantly increased ktr in cMyBP-C
2/2 myocardium and
thereby reduced the variation in ktr with level of activation,
whereas in WT myocardium NEM-S1 evoked near-maximal
ktr values only at very low levels of activation. As seen in
previous studies (37,39) treatment with NEM-S1 did not alter
the maximal rate of force redevelopment in WT or cMyBP-
C2/2 myocardium, again because the cooperative recruit-
ment of cross-bridges is small or negligible during maximal
Ca21 activation (38).
Overall, we found that ablation of cMyBP-C led to marked
acceleration in the rates of force redevelopment during sub-
maximal activation and increased the responsiveness of the
myocardial thin ﬁlament to the activating effects of strong-
binding cross-bridges. Together, these results provide further
support for the idea that cMyBP-C normally acts to modulate
(repress) the interaction of myosin with actin, which in turn
limits steady-state force development and the kinetics of
cross-bridge binding to actin.
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